

CPHI 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



CPHI 2026 Preview – Table of Contents

• <u>New Trends Shaping the Pharma Industry at CPHI 2026</u>	<u>3-5</u>
• <u>Key Sessions To Watch</u>	<u>6-7</u>
• <u>Industry-sponsored Sessions & Focus Areas At CPHI 2026</u>	<u>8-13</u>
• <u>Industry Landscape at a Glance - CPHI 2026</u>	<u>9</u>
• <u>Key Industry-sponsored Sessions At CPHI 2026</u>	<u>10-12</u>
• <u>Emerging Technologies & Strategic Models at CPHI 2026</u>	<u>13</u>
• <u>AI/ML Trends & Strategic Watchpoints At CPHI 2026</u>	<u>14-17</u>
• <u>AI / Digital Health Angle At CPHI 2026</u>	<u>15-16</u>
• <u>What We're Watching For Post-congress</u>	<u>17</u>
• <u>Get In Touch With LucidQuest</u>	<u>18</u>





- **Pharma supply chains are set to shift from efficiency-led models toward resilience and localization**

- The programme is expected to place strong emphasis on API security, supply-chain fragmentation, geopolitical tensions, local-for-local manufacturing and medicine security. Sessions across Global Pharma Outlook and Supply & Formulation Excellence are set to highlight the growing importance of visibility, diversification and regional manufacturing capabilities



- **CDMOs are expected to move beyond capacity provision toward strategic innovation partnerships**

- The programme is set to examine CDMO consolidation, strategic partnerships, technology transfer, manufacturing intelligence and the evolution of CDMOs from capacity providers to “innovation architects.” This is expected to position partnership models, technical capabilities and execution expertise alongside capacity as increasingly important considerations



- **Manufacturing infrastructure is set to become a critical constraint for next-generation medicines**

- Cell and gene therapies, mRNA, ADCs, bispecific antibodies and other advanced modalities are expected to feature prominently across Next-Gen Bio. The programme is set to focus on commercial readiness, aseptic manufacturing, scale-up, fill-finish and infrastructure requirements alongside scientific innovation



- **AI is expected to move from experimentation toward operational deployment in pharma**

- CPHI 2026 is set to feature dedicated AI & Tech programming covering AI agents, AI-ready data, intelligent batch records, AI management systems, digital manufacturing and AI applications across drug development and manufacturing. The emphasis is expected to shift toward scaling AI and demonstrating enterprise value, rather than simply introducing AI capabilities



- **GLP-1s and peptide medicines are expected to create new manufacturing and delivery requirements**

- GLP-1 manufacturing is set to feature across manufacturing, packaging, device and supply-chain sessions, alongside oral peptide delivery, injectable manufacturing, self-injection and large-volume drug delivery. This is expected to position manufacturing and delivery infrastructure as important components of the broader GLP-1 opportunity



- **Sustainability is expected to become increasingly linked to operational competitiveness**

- The Sustainability Spotlight is set to address product carbon footprinting, lifecycle assessment, sustainable procurement, Scope 3 emissions, solvent recovery, greener bioprocessing and sustainable excipients. The discussion is expected to extend beyond corporate targets toward practical manufacturing and supply-chain implementation



Key Sessions To Watch (1/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
06 Oct 2026	New Rules of Global Pharma: When Everything Changes at Once	Global Pharma Outlook	Steffen Saltofte	Sets the broader strategic context for changing pharma priorities, supply security and the evolving global operating environment
06 Oct 2026	CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies?	Manufacturing 5.0	Philip Coetzee / Daiichi Sankyo; Hannah Spaepen / Thermo Fisher Scientific; Kristina Koelerud / LEO Pharma	Expected to explore how CDMO consolidation could reshape outsourcing strategies, partnership models and dependency risks
06 Oct 2026	GLP-1 Manufacturing Evolution: Scaling Innovation for Injectable and Oral Therapies	Manufacturing 5.0	Trishul Shah / T5 Helix Advisory; Hoori Kaskanian / Sandoz	Brings together manufacturing, drug-delivery and market perspectives on the evolving requirements for scaling injectable and oral GLP-1 therapies
06 Oct 2026	Cell & Gene Therapy: Bridging Innovation and Commercial Reality	Next-Gen Bio	Cristina Salado Manzano / Alcura; Fouad Atouf / USP; Lindsay Davies / QVance	Focuses on the operational and manufacturing requirements supporting the transition of cell and gene therapies toward commercial delivery
06 Oct 2026	From AI Tools to AI Colleagues: How Agentic AI Will Transform the Pharmaceutical Enterprise	AI & Tech	Tim Cortinovis	Offers a strategic perspective on the shift from AI tools toward agentic AI and its potential implications for the pharmaceutical enterprise



Key Sessions To Watch (2/2)

Date	Session Title (short)	Type	Author / Institution	Why Watch
07 Oct 2026	Scaling Digital Manufacturing: From Pilot Success to Production Reality	Manufacturing 5.0	oni Manzano / Aizon; Arpan Suryawanshi / Roche; Nima Yazdanpanah / Procegen	Addresses the transition from digital manufacturing pilots to scalable production and the practical considerations involved
07 Oct 2026	How GLP-1 Therapies Are Reshaping Pharmaceutical Manufacturing, Drug Delivery, and Supply Chain Economics	Device & Packaging Innovation	Mike Martin / ISPE	Highlights the potential impact of GLP-1 growth on manufacturing capacity, drug-delivery requirements and supply-chain economics
07 Oct 2026	CDMO Strategic Inflection Point: From Capacity Provider to Innovation Architect	Manufacturing 5.0	Lauren Kjeldsen / Evonik; Eduardo Jule / Lupin Manufacturing; Hubert Scholze / Rezon Bio; Allyson Costa; Bernardo Estupinan	Explores the evolving CDMO role beyond capacity provision, with emphasis on innovation and development partnerships

Industry-Sponsored Sessions & Focus Areas – CPHI 2026





CPHI 2026 - Industry Landscape at a Glance

Strategic Theme	Companies / Participants	Why It Matters
CDMO evolution & consolidation	Thermo Fisher, Catalent, Fujifilm, Lonza, Fresenius Kabi	CPHI 2026 will put the changing role of CDMOs under scrutiny, from capacity provision toward broader development, technology and strategic partnership models
Supply-chain resilience & API security	Catalent, Boehringer Ingelheim, Fresenius Kabi and others	The programme is expected to highlight how supply security, localisation, diversification and upstream visibility could reshape pharma resilience
AI-enabled pharma manufacturing	Thermo Fisher, AI/technology participants	Sessions are set to examine how AI could move beyond pilots toward enterprise deployment, intelligent manufacturing and stronger governance
Next-generation biologics manufacturing	Fujifilm, Thermo Fisher, Lonza, Cytiva	Cell/gene therapy, mRNA, ADCs and bispecific antibodies will create new requirements for scale-up, aseptic processing and commercial manufacturing
GLP-1 manufacturing & delivery	Thermo Fisher, Datwyler, Stevanato and others	CPHI 2026 is set to examine how rising GLP-1 demand could reshape manufacturing scale, oral/injectable formats, delivery systems and supply-chain economics
Sustainable manufacturing & procurement	Catalent, Capsugel and sustainability-focused participants	The programme is expected to highlight how sustainability could increasingly influence process design, procurement, supply-chain transformation and operational resilience
Packaging & drug-device integration	Datwyler, SCHOTT, Stevanato, West and others	Sessions are set to explore how packaging and delivery systems could become more closely integrated with formulation and product development





Key Industry-Sponsored Sessions at CPHI 2026 (1/3)



- **Thermo Fisher Scientific:**

- Focus Areas: CDMO Strategy, AI, Manufacturing Scale-Up & GLP-1s
- The programme will span AI-enabled manufacturing, next-generation medicine capabilities, CDMO consolidation, technology transfer and GLP-1 manufacturing. The focus will position manufacturing scale, digitalisation and strategic outsourcing as interconnected elements of pharma execution



- **Catalent:**

- Focus Areas: Supply-Chain Resilience, APIs, Formulation & Sustainability
- Catalent's programme will centre on supply-chain resilience, API security, upstream risk visibility, complex formulations and greener manufacturing. The sessions will connect formulation and ingredient capabilities with broader supply continuity



Key Industry-Sponsored Sessions at CPHI 2026 (2/3)

- **Fujifilm:**

- Focus Areas: Cell & Gene Therapy, mRNA, ADCs & Biologics Manufacturing
- Fujifilm's presence is going to focus on translating advanced modalities into manufacturing and commercial reality, spanning cell and gene therapy, mRNA, ADCs, bispecific antibodies and manufacturing intelligence

- **Boehringer Ingelheim:**

- Focus Areas: Medicine Security, Global Pharma Strategy & Supply Resilience
- Boehringer Ingelheim will feature prominently across the Global Pharma Outlook programme, covering medicine security, antibiotic manufacturing resilience, biosimilars, geopolitics, market access, licensing and global supply-chain restructuring



Key Industry-Sponsored Sessions at CPHI 2026 (3/3)



- **Datwyler:**

- Focus Areas: Packaging, GLP-1s, Biologics & Drug Delivery
- Datwyler's programme are set to examine packaging and device requirements for biotherapies, biosimilars and GLP-1s, alongside self-injection, rare-disease delivery, 3D-printed delivery experiences and large-volume drug delivery





Emerging Technologies & Strategic Models at CPHI 2026

Asset / Company	2026 Presence
Agentic AI & AI Agents	Moving from conventional AI tools toward AI agents and enterprise-level applications across pharma
Digital & Predictive Manufacturing	Scaling digital manufacturing, predictive analytics and AI-enabled operational decision-making
Continuous Manufacturing	Advancing continuous tableting and continuous biomanufacturing toward commercial-scale implementation
Next-Generation Biologics Manufacturing	Addressing manufacturing infrastructure and execution requirements for cell & gene therapies, ADCs and other complex modalities
GLP-1 & Peptide Manufacturing	Scaling injectable and oral therapies while addressing manufacturing, delivery and supply-chain requirements
Advanced Drug-Device Systems	Evolving autoinjectors, combination products, packaging and delivery technologies for next-generation therapies
Resilient & Localised Supply Chains	Shifting toward local-for-local manufacturing, API security and diversified supply networks
Strategic CDMO Partnerships	CDMOs increasingly positioned around innovation, development capabilities and strategic partnerships rather than capacity alone





AI / Digital Health Angle at CPHI 2026 (1/2)

- **AI is moving beyond isolated pilots toward enterprise-scale deployment across pharma manufacturing, quality and operations. The CPHI 2026 programme is set to examine how AI agents, intelligent batch records, predictive analytics and AI management systems can become embedded within regulated manufacturing environments**
- **Key AI & Digital Manufacturing Themes**
- **From AI Pilots to Enterprise Value**
 - Sessions will focus on the transition from experimentation to scalable AI adoption, with emphasis on demonstrating measurable operational value rather than maintaining standalone pilots
- **Agentic AI in Pharma Operations**
 - The programme is expected to explore the emergence of AI agents and their potential role in automating and supporting complex pharmaceutical workflows, moving beyond conventional AI tools toward more autonomous systems
- **AI-Ready GxP & Manufacturing Infrastructure**
 - Discussions around intelligent GxP ecosystems, AI management systems and AI-driven batch records highlight the need for appropriate governance, data foundations and control frameworks before AI can scale across regulated operations



AI / Digital Health Angle at CPHI 2026 (2/2)

- **Predictive & Intelligent Manufacturing**

- AI applications are set to extend into manufacturing performance, cleanroom optimisation, process intelligence and predictive decision-making, supporting a shift from reactive operations toward more data-driven manufacturing

- **Key sessions include:**

- From AI Tools to AI Colleagues: How Agentic AI Will Transform the Pharmaceutical Enterprise
- Building and Validating AI Agents for Pharma
- From AI Pilots to Enterprise Value: Scaling AI Adoption in Biopharma
- Building an Intelligent GxP Ecosystem: Leveraging AI-Driven Technology and Intelligent Batch Records for Pharma
- How AI is Compressing Drug Development and Manufacturing Timelines
- AI Management System: How to Ensure a State of Control Across AI Applications
- From Data to Efficiency: Unlocking Cleanroom Performance with Predictive AI
- Keynote: Building Operational Readiness for AI for Scale
- Panel: AI Ask Us Anything: The Scale-Up Edition



What We're Watching for Post-CPHI 2026

- Whether CDMOs increasingly position themselves as strategic development and innovation partners rather than capacity providers alone.
- Whether supply-chain resilience translates into greater localisation, diversification and site-neutral manufacturing strategies
- Whether AI moves from proof-of-concept projects into validated, production-scale pharma workflow
- Whether manufacturing infrastructure keeps pace with cell/gene therapies, ADCs, mRNA, bispecifics and other complex modalities
- How GLP-1 demand influences manufacturing capacity, formulation, drug delivery and supply-chain models
- Whether sustainability becomes more directly embedded into procurement, manufacturing and supply-chain decisions
- Whether packaging and device co-development becomes increasingly important as biologics and self-administered therapies expand

Strategic Insights and Strategy Development is our focus



COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM